Abstract: |
A unique mRNA produced in leukemic cells from a t(15; 17) acute promyelocytic leukemia (APL) patient encodes a fusion protein between the retinoic acid receptor α (RARα) and a myeloid gene product called PML. PML contains a cysteine-rich region present in a new family of apparent DNA-binding proteins that includes a regulator of the interleukin-2 receptor gene (Rpt-1) and the recombination-activating gene product (RAG-1). Accordingly, PML may represent a novel transcription factor or recombinase. The aberrant PML-RAR fusion product, while typically retinoic acid responsive, displays both cell type- and promoter-specific differences from the wild-type RARα. Because patients with APL can be induced into remission with high dose RA therapy, we propose that the nonliganded PML-RAR protein is a new class of dominant negative oncogene product. Treatment with RA would not only relieve this inhibition, but the activated PML-RAR protein may actually promote myelocyte differentiation. © 1991. |
Keywords: |
human cell; dna-binding proteins; case report; polymerase chain reaction; gene expression; transcription factor; transcription factors; oncogenes; leukemia, promyelocytic, acute; dna; amino acid sequence; molecular sequence data; rna, messenger; leukemia cell; carrier proteins; recombinant protein; acute myeloblastic leukemia; chromosome translocation; base sequence; blotting, northern; oligonucleotides; chromosomes, human, pair 17; chromosomes, human, pair 15; tretinoin; receptors, retinoic acid; trans-activation (genetics); human; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; translocation (genetics); retinoic acid binding protein
|